SecBot SecBot
8-K ·Filed Apr 27, 2026

MIRM

Mirum Pharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago SEC0001193125-26-179048
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Position for potential upside ahead of Phase 3 topline data in H2 2026; monitor for signs of commercial preparation and regulatory engagement. The strong efficacy and safety profile support brelovitug as a best-in-class candidate in HDV, a space with high unmet need.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$92.48
T+0 close · Apr 27, 2026 · via day close
Latest settled
+23.79%
T+60 · $114.48
Vs SPY
+19.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $92.48entry
  2. T+1 · 7mo ago +1.64%α +2.13% · $94.00
  3. T+5 · 7mo ago +14.39%α +13.99% · $105.79
  4. T+20 · 6mo ago +6.94%α +1.99% · $98.90
  5. T+60 · 4mo ago +23.79%α +19.01% · $114.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mirum Pharmaceuticals announced positive Phase 2b results for brelovitug in treating chronic hepatitis delta virus (HDV), with 100% and 75% virologic response rates in the two dose groups versus 0% in the control. The drug was well tolerated, supporting its potential as a single-agent therapy and advancing the program toward Phase 3 topline data in H2 2026.

Key Facts

  • Brelovitug met primary endpoint in Phase 2b AZURE-1 study for chronic HDV treatment
  • 100% of patients in 300 mg QW arm and 75% in 900 mg Q4W arm achieved virologic response vs. 0% in delayed treatment arm
  • Primary composite endpoint (virologic response + ALT normalization) achieved in 45% and 35% of patients, respectively
  • Treatment was well tolerated with no grade 3+ treatment-related adverse events and no discontinuations due to AEs
  • Full results to be presented at EASL Congress in May 2026; Phase 3 topline data expected in H2 2026, with potential BLA submission and U.S. launch in 2027

Financial Impact

Significant positive impact on valuation potential; drug advancement reduces development risk for a high-unmet-need indication with no approved therapies

R&D pipeline valuefuture revenue potentialmarket sentiment

Risk Factors

  • Phase 3 results may not replicate Phase 2b efficacy
  • Regulatory requirements may exceed current expectations
  • Competition could emerge before 2027 launch

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-179048
Document: 0001193125-26-179048-index-headers.html0001193125-26-179048
Document: 0001193125-26-179048-index.html0001193125-26-179048
Document: 0001193125-26-179048.txt0001193125-26-179048

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026